The acquisition provides Hetero with a strong front-end marketing presence, the required commercial infrastructure, product portfolio, and manpower to enter Spain.
Drug maker Hetero Labs said on January 2 that its European subsidiary Amarox has acquired Tarbis Farma, a company operating in Spain from Grupo Ferrer Internacional.
Hetero is one of India's largest privately held drug maker with revenues of Rs 4,726 crore in FY17. The company is the world's largest producer of anti-retroviral drugs.
The company didn't disclose the financial details of the deal.
The acquisition provides Hetero with a strong front-end marketing presence, giving Amarox the required commercial infrastructure, product portfolio, manpower for a seamless entry into the retail, hospital, and tender business channels in Spain.
Tarbis Farma comes with a robust product portfolio and an extensive marketing network with well-experienced personnel in retail business across Spain, the company said.
"The acquisition fits very well with Hetero's growth strategy in EU giving Amarox a platform to reach out to the customers in a robust way with the present portfolio and Hetero's pipeline of products," said AV Narasa Reddy, Executive Director of Hetero.
The buyer and seller were advised by Crowe and Deloitte respectively.
